KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 35

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Pipeline Review, H2 2016', provides in depth analysis on KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) targeted pipeline therapeutics.

The report provides comprehensive information on the KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R)

  • The report reviews KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) targeted therapeutics and enlists all their major and minor projects

  • The report assesses KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) Overview 6
Therapeutics Development 7
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Products under Development by Stage of Development 7
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Products under Development by Therapy Area 8
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Products under Development by Indication 9
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Products under Development by Companies 12
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Products under Development by Universities/Institutes 14
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Companies Involved in Therapeutics Development 23
Crinetics Pharmaceuticals, Inc. 23
Millennium Pharmaceuticals Inc 24
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Drug Profiles 25
Kisspeptin-10 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
kisspeptin-54 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
TAK-448 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Discontinued Products 31
KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Featured News & Press Releases 32
Jan 28, 2015: Crinetics Pharmaceuticals Awarded $1.5MM NIH Phase-II SBIR Grant to Develop Kisspeptin Receptor Antagonists for PCOS and Other Women's Health Diseases 32
Jun 18, 2013: Kisspeptin hormone could make IVF safer for mothers 32
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 23
Pipeline by Millennium Pharmaceuticals Inc, H2 2016 24
Discontinued Products, H2 2016 31

List of Figures

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
    Published: 13-Feb-2017        Price: US 2950 Onwards        Pages: 311
    DelveInsight's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors. This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with arou......
  • 3D Bioprinting Market by Technology (Microextrusion, Inkjet, Laser, Magnetic), Material (Cells, Hydrogels, Extracellular Matrices, Biomaterials), Application (Clinical (Bone, Cartilage, Skin) & Research (Regenerative Medicine)) - Global Forecasts to 2021
    Published: 01-Feb-2017        Price: US 5650 Onwards        Pages: 143
    The 3D bioprinting market is expected to reach USD 1,332.6 million by 2021, at a CAGR of 26.5% from 2016 to 2021. The 3D bioprinting market is primarily driven by the rising demand for organ transplantation across the globe. In addition, growing R&D in the field of 3D bioprinting, increasing public and private investments to support 3D bioprinting research, and rising use of 3D bioprinting in drug discovery are supporting the growth of this market. On the other hand, limitations o......
  • 3SBio Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand 3SBio and its partnering interests and activities since 2010 Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company reports a......
  • Acorda Therapeutics Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Acorda Therapeutics and its partnering interests and activities since 2010 Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand com......
  • Bavarian Nordic Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Bavarian Nordic and its partnering interests and activities since 2010 Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company......
  • Biogen Idec Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Biogen Idec and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company re......
  • Biomarin Pharmaceuticals Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Biomarin Pharmaceuticals and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On dema......
  • Enzo Biochem Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Enzo Biochem and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company r......
  • Genentech Partnering Deals and Alliances 2010 to 2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary This report provides all the information you require to better understand Genentech and its partnering interests and activities since 2010. Description The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On demand company repo......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs